|Title:||Carbohydrate Ligands for COVID-19 Spike Proteins||Authors:||Lee, Yung-Kuo
|Keywords:||INHIBITS ENTEROVIRUS-71 INFECTION;BLOOD-GROUP ANTIGENS;SIALIC-ACID;NUCLEOTIDE-SEQUENCE;BINDING-SITE;RECEPTOR;VIRUS;CORONAVIRUSES;1-DEOXYMANNOJIRIMYCIN;SPECIFICITY||Issue Date:||Feb-2022||Publisher:||MDPI||Journal Volume:||14||Journal Issue:||2||Source:||VIRUSES-BASEL||Abstract:||
An outbreak of SARS-CoV-2 coronavirus (COVID-19) first detected in Wuhan, China, has created a public health emergency all over the world. The pandemic has caused more than 340 million confirmed cases and 5.57 million deaths as of 23 January 2022. Although carbohydrates have been found to play a role in coronavirus binding and infection, the role of cell surface glycans in SARS-CoV-2 infection and pathogenesis is still not understood. Herein, we report that the SARS-CoV-2 spike protein S1 subunit binds specifically to blood group A and B antigens, and that the spike protein S2 subunit has a binding preference for Le(a) antigens. Further examination of the binding preference for different types of red blood cells (RBCs) indicated that the spike protein S1 subunit preferentially binds with blood group A RBCs, whereas the spike protein S2 subunit prefers to interact with blood group Le(a) RBCs. Angiotensin converting enzyme 2 (ACE2), a known target of SARS-CoV-2 spike proteins, was identified to be a blood group A antigen-containing glycoprotein. Additionally, 6-sulfo N-acetyllactosamine was found to inhibit the binding of the spike protein S1 subunit with blood group A RBCs and reduce the interaction between the spike protein S1 subunit and ACE2.
|Appears in Collections:||生命科學暨生物科技學系|
03 GOOD HEALTH AND WELL-BEING
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.